Navigation Links
Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug
Date:6/22/2009

estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding the timing and expected results of the ATPotent(TM) proof-of-concept clinical trial in Italy, the statements regarding the timing of ATPace(TM)'s expected entry into a pivotal Phase 2b/3 clinical trial for the treatment of paroxysmal supraventricular tachycardia, the timing of CDP-1050's expected commencement of a Phase 2 clinical trial for the treatment of heart failure, the expected results of the use of ATPace(TM) and the estimated PSVT market. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the data derived from the trials may not be sufficient to support marketing of approval of the products, clinical trial for approval of ATPace(TM) and the Phase 2 clinical trial for our CDP-1050 may not be successful, the results of the clinical trial for ATPotent(TM) may not be as expected, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, the market may not be as anticipated and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex's most recently filed SEC documents, such as its m
'/>"/>
SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
2. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
3. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
4. VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers
5. Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC
6. Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs
7. Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan
8. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
9. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
10. Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
11. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN ANTONIO , Jan. 15, 2014 Most ... take, according to a recent online survey* sponsored by ... among the National Osteoporosis Foundation online support community, ... to take medication that comes in a form other ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... , MOUNTAIN VIEW, Calif. , Jan. ... of a Phase I clinical trial of CCX168, an ... is a highly potent and very selective compound that ... the body,s complement system and a potent driver of ...
... , EXTON, Pa. , Jan. 28 ... medical technology company that provides innovative solutions and technologies for a ... three and six months ended December 31, 2009 . All ... to those provided in the Company,s January 15, 2010 ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 2ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 3ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 4Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 2Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 3Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 4Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 5Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 6Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 7Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 8Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 9Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 10Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 11Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 12Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 13Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 14Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 15Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 16Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 17Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 18Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 19Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 20
(Date:4/24/2014)... the influenza pH1N1 virus caused the first flu pandemic ... May 2009 and killed more than 50 people in ... mainly during flu epidemics (winter/spring seasons). , Infections ... complicated illnesses. World Health Organization has recommended Tamiflu for ... disadvantage of this drug is that it targets viral ...
(Date:4/23/2014)... Using frozen stool from healthy, unrelated donors was ... relapsing diarrhea caused by Clostridium difficile , ... Clinical Infectious Diseases and available online. ... equally effective whether given via a colonoscope or ... may make this promising treatment more readily available ...
(Date:4/23/2014)... University Spokane have developed a new way to ... behind the wheel. , Their recently patented technology ... variable in drowsy driversand offers an affordable and ... drowsiness detection systems. , Van Dongen"Video-based systems that ... drifting out of its lane are cumbersome and ...
(Date:4/23/2014)... Society for Radiation Oncology (ASTRO) has issued a ... for Endometrial Cancer: An ASTRO Evidence-Based Guideline," that ... the treatment of endometrial cancer. The guideline,s executive ... of Practical Radiation Oncology (PRO), the ... guideline is available as an open-access article online ...
(Date:4/23/2014)... pathway that helps prevent new cells from receiving too ... been directly linked to cancer and other diseases. , ... the end of cell division, the enzyme Cdc14 activates ... are fully repaired before the parent cell distributes copies ... safeguard against some of the most devastating genome errors, ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:WSU innovation improves drowsy driver detection 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... , THURSDAY, Aug. 25 (HealthDay News) -- Alzheimer,s disease is ... the announcement by celebrated women,s basketball coach Pat Summit of ... on the less common, but perhaps even more devastating, form ... United States, or about 5 percent of those with Alzheimer,s, ...
... (HealthDay News) -- Your immune system response to a flu ... that immune reaction can be observed through gene activity, according ... genes in 267 blood samples from 17 healthy volunteers who ... complex differences in the immune responses between the half of ...
... Reinberg HealthDay Reporter , THURSDAY, Aug. 25 ... higher odds of dying if they,re admitted over the ... finds equally good results for patients treated at comprehensive ... so-called "weekend effect" -- an increased risk of death ...
... University researchers have successfully re-engineered the protein-making machinery in ... revolutionize the study and treatment of a variety of ... E. coli , which allows us synthesize special ... states," said Jesse Rinehart of the Department of Cellular ...
... Providing access to an outpatient clinic isn,t enough to keep ... from returning to the emergency department (ED) for follow-up care, ... dressing changes, according to new Johns Hopkins research. Reporting ... say that patients with Medicaid, Medicare and those with no ...
... Thomas Jefferson University , among other institutions, including ... developed single vaccines to protest against both rabies and ... bivalent vaccines have several advantages over other Ebola candidates ... humans and primates. It,s built on the same platform ...
Cached Medicine News:Health News:Coach Summitt's Diagnosis Puts Spotlight on Early-Onset Alzheimer's 2Health News:Coach Summitt's Diagnosis Puts Spotlight on Early-Onset Alzheimer's 3Health News:Coach Summitt's Diagnosis Puts Spotlight on Early-Onset Alzheimer's 4Health News:Specialized Stroke Centers Deliver on the Weekends 2Health News:Specialized Stroke Centers Deliver on the Weekends 3Health News:Yale researchers use genetic code to engineer a living protein 2Health News:Uninsured trauma patients are more likely to use the ED for follow-up care 2Health News:Uninsured trauma patients are more likely to use the ED for follow-up care 3Health News:Single vaccines to protect against both rabies and Ebola 2
RapidStrep A test is a qualitative test that detects group A,streptococcal antigen. The test is a rapid, in vitro assay. It is,intended for professional use to help diagnose Strep A,infection i...
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
Inquire...
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
Medicine Products: